Objective: Given their reported function in phagocytosis and clearance of protein aggregates in Alzheimer disease (AD), we hypothesized that variants in ATP-binding cassette transporter A7 (ABCA7) might be involved in Parkinson disease (PD).
Recent studies have identified ABCA7 (ATP-binding cassette transporter A7) as a risk factor for AD through genome-wide association studies in large case-control data sets. 10, 11 Subsequent sequencing efforts have identified multiple rare loss-of-function (LOF) variants associated with AD risk (OR z 2). [12] [13] [14] ABCA7 is reported to be involved in the transport of phospholipid and cholesterol across membranes to ApoE. 15 Alternatively, ABCA7 has been implicated in the activation of phagocytosis to clear amyloid plaques or even apoptotic cells. 16, 17 Overall, ABC transporters are functional throughout the brain, although most are at the blood-brain barrier. 18 These transporters have been reported to be involved in several disorders, including PD (e.g., ABCB1 or multidrug resistance gene [MDR1], PD 19 ; ABCC7 or cystic fibrosis transmembrane conductance regulator [CFTR] , cystic fibrosis 20 ; ABCA1, Tangier disease 21 and AD 22 ; ABCA13, bipolar disorder 23 ). Given ABCA7's potential function in protein clearance through the phagocytic pathway and the overlap between AD and PD, we hypothesized that ABCA7 is a likely candidate gene for PD. We present a report of ABCA7 LOF variants in 2 large sequencing data sets of patients with PD and healthy controls.
METHODS Sample selection. Patients included in this study were collected by the University of Miami Morris K. Udall Parkinson Disease Research Center of Excellence (J.M.V., principal investigator) and 13 centers of the Parkinson Disease Genetics Collaboration. 24 Neurologists, most of whom were movement disorder specialists, examined all the patients and healthy controls. A standard neurologic examination including the Unified Parkinson's Disease Rating Scale was performed and has been described previously. 25 Unaffected individuals demonstrated no signs of the disease at age at examination (AAE). A total of 411 unrelated patients with PD and 231 unrelated control individuals were included for whole-exome sequencing (WES). Principal component analyses (PCAs) were performed twice using either common or rare variants detected through the WES (threshold minor allele frequency [MAF] 5% in both Exome Variant Server and 1000 Genomes Project). We identified 24 outliers (15 patients and 9 healthy controls) due to either population substructure (not clustering with white, nonHispanic HapMap reference samples in common variant PCA) or excessive sequence errors/contamination (in rare variant PCA). The remaining 396 patients and 222 healthy control individuals are all of white, non-Hispanic/Latino descent.
Standard protocol approvals, registrations, and patient consents. All participants of the collaboration were collected after approval by each contributing center's institutional review board and provided written informed consent.
Sequence capture, sequencing, alignment, and variant calling. Fragmented DNA was captured using the Agilent SureSelect Human All Exon Kit (Agilent Technologies, Santa Clara, CA), designed to cover 38 Mb or 50 Mb of human genomic sequences. We used the 38 Mb capture kit in the initial 15 individuals (all patients); the remaining samples (N 5 603) were processed using the 50 Mb version 3 kit. The libraries were loaded onto an Illumina cBot for cluster generation (Illumina, San Diego, CA). The primer-hybridized flow cells were then transferred to HiSeq2000 sequencers and paired-end sequencing was performed in a 2 3 101b mode (Illumina). The base calling was performed by Illumina CASAVA 1.6 pipeline and aligned to hg19 using Genome Analysis Tool Kit (GATK) v1.1. The Unified Genotyper from GATK performs variant quality score (VQS) recalibration and genotype refinement to make accurate variant calls. 26 Statistical analysis. The cumulative association of functional variants with PD was assessed by a 2 3 2 contingency table analysis. The association of PD with the frequency of functional variants in cases and controls from both data sets combined was evaluated by calculating the OR and statistical significance using a 1-tailed Fisher exact test. Two parallel analyses were used: one for all LOF variants and a second for those rare variants (MAF ,5% in 1000 Genomes) with CADD .20. 
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DISCUSSION This study expands the growing clinical, pathologic, and genetic overlap between PD and AD. We were able to identify known LOF ABCA7 variations in patients with PD and demonstrate a strong association of PD with ABCA7 LOF (OR 5 4.94) and putative highly functional variants (OR 5 2.85), although the observed enrichment was not quite statistically significant (p 5 0.07 LOF variants or p 5 0.06 CADD .20 rare variants). The rare frequency of these variants and the relatively small sample size (particularly for the controls) limited our power to detect significant association with rare variants. Three of the 7 described LOF variants have not been previously reported in patients with AD (p.R1754X, p.L737CfsX60, and p.P1205fsX12). All are very rare in the Exome Aggregation Consortium database (allele frequency of p.R1754X and p.1205fsX12 ,5 3 10 25 and p.L737CfsX60 was not seen). In addition, we identified the variant p.L1403RfsX7 in only 3 patients and not in controls, which supports the original observed enrichment of this variant in only patients with AD.
12,14 Both p.E709AfsX86 and p.W1214X have been reported as strong AD risk factors and shown to reduce ABCA7 expression. 12, 14 Although the onset age of PD in the latter 2 LOF carriers (tables 2 and 3) is earlier than that reported for AD carriers (range 54-90 years and 84 years, respectively), 12 it is within the range expected for classical PD. We observed an additional 10 putative highly functional non-LOF variants with CADD .20. Prior knowledge of the LOF variants that contribute to AD risk and the rarity of all functional variants strongly suggests that ABCA7 also contributes to PD risk.
One control with an LOF variant was identified (p. W1214X in PPMI data set). However, the individual is relatively young, with AAE of 56 years and presented with signs of arm rigidity upon activity. Therefore, disease status appears unclear for this individual.
The presence of cognitive changes in some of the LOF carrier patients (tables 2 and 3) is of obvious interest. On average, the LOF cases in the Udall WES were followed for ;6 years without any indication of cognitive changes. The autopsied LOF cases (in the Udall WES) presented with pathologic signs of AD along with obvious PD changes confirming PD diagnosis. The patients with the p.W1214X (AD Braak stage III) and p.L1403RfsX7 variants (AD Braak stage V) still presented with no cognitive changes at their last clinical examination (table 2; individual 1 5 years before death and individual 3 1 year before death). In contrast, the PPMI patients carrying p.W1214X and p.P1205QfsX12 are reported to present with some signs of cognitive decline on clinical examination (table 3, individuals 3278 and 3866). As some cognitive decline was reported and AD has a later onset age than that of PD in general, we cannot exclude concomitant disease in these individuals with reported cognitive decline or AD pathology. However, dementia is common in patients with PD, 1, 2 and AD pathology is observed in a relatively high proportion of both patients with PD 28 and healthy individuals upon death, 29 placing these observations in line with the expected PD process and commonalities of the 2 disorders. Additional autopsy studies will be needed to further investigate the AD pathologic features in PD ABCA7 variant carriers.
Overall, our data suggest that ABCA7 functional variants (LOF or variants with CADD .20) represent rare variant risk factors for clinical PD. The identification of LOF variants in both patients with AD and patients with PD implies that ABCA7 is involved in both disorders. Given ABCA7's reported function in phagocytosis and clearance of protein aggregates, a likely mechanism for ABCA7 variants would be the decreased clearance of b-amyloid and a-synuclein in AD and PD. It would be interesting to investigate the presence of ABCA7 variants in other protein accumulation disorders.
This and other studies have now implicated several ABC transporters in neurologic, specifically neurodegenerative, diseases, [19] [20] [21] [22] [23] which implies that ABC transporters (and ABCA7 specifically) are interesting candidate genes for neurodegeneration in general. 
